Medicilon, a China-based, one-stop pharmaceutical preclinical research and development CRO, announced on Monday that it has named Dr Qingcong Lin as the president of Medicilon USA Corp in Boston.

In the new role, Dr Lin is to head the company to explore new paradigms in cutting-edge fields, drive the company to achieve broader and deeper cooperation globally, and empower drug innovations.

Dr Lin has experience working in the pharmaceutical R&D field for around 40 years. He has served in positions such as senior scientist II, principal research scientist I & II, and director of Molecular Genetics Laboratory at Wyeth Research; principal research scientist II and group leader at Pfizer Research; Senior VP of Biology and Antibody R&D at Shenogen Pharma Group; and SVP of Beijing Biocytogen, CEO of Biocytogen Boston Corp. He has set up subsidiary companies for multinational corporations, built multiple scientific teams, and has drug R&D experience.